| human | Q5 |
| P496 | ORCID iD | 0000-0002-0160-3634 |
| P1153 | Scopus author ID | 47160915900 |
| P108 | employer | Istituto Neurologico Mediterraneo | Q30282155 |
| P735 | given name | Enrico | Q16908530 |
| Enrico | Q16908530 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q45305588 | Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease. |
| Q33644718 | Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease |
| Q47273613 | De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease |
| Q33902931 | Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease |
| Q37580232 | Early defect of transforming growth factor β1 formation in Huntington's disease. |
| Q39049796 | FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. |
| Q41340916 | Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models |
| Q38766477 | Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease |
| Q41842714 | Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice |
| Q47594904 | Neuromedin U potentiates ADP- and epinephrine-induced human platelet activation |
| Q35107991 | Nitric oxide dysregulation in platelets from patients with advanced Huntington disease. |
| Q38861728 | Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model |
| Q45295362 | Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease |
Search more.